PMID- 34083121
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211204
IS  - 1347-4421 (Electronic)
IS  - 1347-4421 (Linking)
VI  - 132
IP  - 3
DP  - 2021 Sep
TI  - Lactiplantibacillus plantarum 22A-3 isolated from pickle suppresses 
      ovalbumin-induced food allergy in BALB/c mice and 
      2,4-dinitrochlorobenzene-induced atopic dermatitis in NC/Nga mice.
PG  - 271-278
LID - S1389-1723(21)00119-5 [pii]
LID - 10.1016/j.jbiosc.2021.05.001 [doi]
AB  - In the previous study, pickle-derived Lactiplantibacillus plantarum 22A-3 
      (LP22A3) suppressed ear edema in passive cutaneous anaphylaxis by its oral 
      administration. Moreover, LP22A3 treatment directly to RBL-2H3 cells shows no 
      effect on beta-hexosaminidase release from RBL-2H3 but inhibited its release using 
      the Caco-2/RBL-2H3 cells co-culture system stimulated with LP22A3 from the apical 
      side. In this study, oral administration of LP22A3 decreased total IgE and 
      ovalbumin (OVA) specific IgE contents in blood of BALB/c mice induced food 
      allergy by OVA. Moreover, its oral administration suppressed the development of 
      dermatitis induced by 2,4-dinitrochlorobenzene (DNCB) which was used to develop 
      atopic dermatitis-like lesions in NC/Nga mice. This alleviation was further 
      correlated with a reduction of elevated serum total IgE, transepidermal water 
      loss and elevated acanthosis in the LP22A3-treated group compared with 
      vehicle-treated positive group. In co-culture system composed of Caco-2 and 
      RBL-2H3 cells, LP22A3 treatment on apical side before or after the sensitization 
      with anti-dinitrophenyl (DNP) IgE antibody indicated the different effect on 
      beta-hexosaminidase release from RBL-2H3. Its treatment before the sensitization 
      decreased beta-hexosaminidase release, but not after sensitization, indicating that 
      LP22A3 affected mast cells sensitized with allergen through intestinal epithelial 
      cells. These results suggest that LP22A3 may have a potential therapeutic 
      property for Type 1 hypersensitivity and atopic dermatitis.
CI  - Copyright (c) 2021 The Society for Biotechnology, Japan. Published by Elsevier B.V. 
      All rights reserved.
FAU - Mizuno, Masashi
AU  - Mizuno M
AD  - Department of Agrobioscience, Graduate School of Agricultural Science, Kobe 
      University, 1-1 Rokkodai-cho, Nada-ku, Kobe 657-8501, Japan. Electronic address: 
      mizuno@kobe-u.ac.jp.
FAU - Ohto, Nobuaki
AU  - Ohto N
AD  - Maruzen Pharmaceuticals Co. Ltd., 1089-8 Sagata, Shinnichi-cho, Fukuyama 
      729-3102, Japan.
FAU - Kuwahara, Hiroshige
AU  - Kuwahara H
AD  - Maruzen Pharmaceuticals Co. Ltd., 1089-8 Sagata, Shinnichi-cho, Fukuyama 
      729-3102, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210601
PL  - Japan
TA  - J Biosci Bioeng
JT  - Journal of bioscience and bioengineering
JID - 100888800
RN  - 0 (Dinitrochlorobenzene)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Caco-2 Cells
MH  - *Dermatitis, Atopic/chemically induced/drug therapy
MH  - Dinitrochlorobenzene
MH  - *Fermented Foods
MH  - *Food Hypersensitivity/drug therapy
MH  - Humans
MH  - Mast Cells
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovalbumin
OTO - NOTNLM
OT  - Anti-allergic activity
OT  - Atopic dermatitis
OT  - Lactiplantibacillus plantarum 22A-3
OT  - Transforming growth factor-beta
OT  - beta-Hexosaminidase
EDAT- 2021/06/05 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/06/04 05:50
PHST- 2021/02/10 00:00 [received]
PHST- 2021/04/27 00:00 [revised]
PHST- 2021/05/07 00:00 [accepted]
PHST- 2021/06/05 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2021/06/04 05:50 [entrez]
AID - S1389-1723(21)00119-5 [pii]
AID - 10.1016/j.jbiosc.2021.05.001 [doi]
PST - ppublish
SO  - J Biosci Bioeng. 2021 Sep;132(3):271-278. doi: 10.1016/j.jbiosc.2021.05.001. Epub 
      2021 Jun 1.